Remicut ® (emedastine difumarate) is a new anti-allergic agent which has been reported to produce a potent anti-histaminic activity. We evaluated the efficacy (especially, regarding the number of days required to show an improvement) of this agent taken 2 weeks by 38 patients (18 males and 20 females ) with perennial allergic rhinitis.
1) The final global improvement rate (either “improved” or better) was 64.0%.
2) The overall safety rate (“no side effects”) was 83.9%.
3) The global utility rate (“useful” or better) was 80.0%
4) Regarding the subjective symptoms, a high improvement rate of nasal obstruction (“improved” or better) was characteristic (58.3%)
5) The number of days required to show an improvement was as follows: sneezing-3.7 days, and sniveling-3.9 days, nasal obstruction-5.7 days.
6) Side effects consisting mainly of sleepiness occurred in 5 patients. No abnormal laboratory findings were observed.
These results thus indicate that emedastine difumarate is useful in treating perennial allergic rhinitis, especially in order to obtain an improvement in nasal obstruction symptoms.
View full abstract